Viewing Study NCT03711032

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:24 PM
Ignite Modification Date: 2026-02-02 @ 1:52 AM
Study NCT ID: NCT03711032
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-22
First Post: 2018-10-15
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Sponsor: Merck Sharp & Dohme LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None High-risk Non-muscle Invasive Bladder Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None programmed cell death receptor 1 (PD-1) View
None programmed cell death ligand 1 (PD-L1) View
None anti-PD-1 View
None anti-PD-L1 View
None BCG View
None HR NMIBC View
None Patient Reported Outcome (PRO) View